YPOG Advises Evotec and Venrock Healthcare Capital Partners on Sale of Tubulis to Gilead for Up to USD 5 Billion

"YPOG, working with two separate teams, advised Evotec SE and Venrock Healthcare Capital Partners on the sale of clinical-stage ADC developer Tubulis to Gilead for up to USD 5 billion—USD 3.15 billion upfront plus up to USD 1.85 billion in contingent payments. The deal is expected to close in Q2 2026. Tubulis develops next‑generation antibody‑drug conjugates, including lead clinical candidate TUB‑040 for ovarian and other solid tumors. Evotec backed Tubulis in its Series B/B2 rounds and Venrock led the Series C; YPOG advised both sellers (Venrock’s team was also supported by U.S. firm Cooley LLP)."